ES2132373T3 - Benzocicloheptenos, benzoxepinas y benzotiepinas. - Google Patents

Benzocicloheptenos, benzoxepinas y benzotiepinas.

Info

Publication number
ES2132373T3
ES2132373T3 ES94902708T ES94902708T ES2132373T3 ES 2132373 T3 ES2132373 T3 ES 2132373T3 ES 94902708 T ES94902708 T ES 94902708T ES 94902708 T ES94902708 T ES 94902708T ES 2132373 T3 ES2132373 T3 ES 2132373T3
Authority
ES
Spain
Prior art keywords
pct
group
sec
bond
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902708T
Other languages
English (en)
Inventor
Jean-Jacques Berthelon
Michel Brunet
Marc Noblet
Philippe Durbin
Daniel Les Jardins De Guerrier
Trong Nghia Impasse Des Luong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2132373T3 publication Critical patent/ES2132373T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL (I), EN LA QUE X REPRESENTA O O CHR: R1, R2, R3 Y R4 QUE SON IDENTICO O DIFERENTES REPRESENTAN UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO C1C7, QUE ES POSIBLE PARA R1 FORMAR ADICIONALMENTE UN ENLACE CON R, R3 REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO HIDROXILO, O R5, TOMADO JUNTO CON R7 FORMA UN ENLACE O UN GRUPO O, R6 REPRESENTA UN GRUPO DE FORMULA (A) EN EL QUE R10 Y R11 TOMADOS JUNTOS CON LOS ATOMOS DE CARBONO A LOS QUE ESTAN LIGADOS, FORMAN UN GRUPO HETEROCICLICO NITROGENOSO Y SU NB-OXIDOS FARMACEUTICAMENTE ACEPTABLES. ESTOS COMPUESTOS SON POTENTES ACTIVADORES DE CANALES DE POTASIO.
ES94902708T 1992-12-07 1993-12-07 Benzocicloheptenos, benzoxepinas y benzotiepinas. Expired - Lifetime ES2132373T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9214720A FR2698873B1 (fr) 1992-12-07 1992-12-07 Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.

Publications (1)

Publication Number Publication Date
ES2132373T3 true ES2132373T3 (es) 1999-08-16

Family

ID=9436308

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902708T Expired - Lifetime ES2132373T3 (es) 1992-12-07 1993-12-07 Benzocicloheptenos, benzoxepinas y benzotiepinas.

Country Status (29)

Country Link
US (2) US5602152A (es)
EP (1) EP0626954B1 (es)
JP (1) JPH07503977A (es)
KR (1) KR100236810B1 (es)
CN (1) CN1050127C (es)
AT (1) ATE177742T1 (es)
AU (1) AU680856B2 (es)
CA (1) CA2129642A1 (es)
CZ (1) CZ184894A3 (es)
DE (1) DE69324001T2 (es)
DK (1) DK0626954T3 (es)
ES (1) ES2132373T3 (es)
FI (1) FI943646A0 (es)
FR (1) FR2698873B1 (es)
GR (1) GR3030514T3 (es)
HU (1) HUT67852A (es)
IL (1) IL107891A0 (es)
LT (1) LT3167B (es)
LV (1) LV10451B (es)
NO (1) NO942914L (es)
NZ (1) NZ258896A (es)
PL (1) PL174246B1 (es)
RO (1) RO113040B1 (es)
RU (1) RU2127268C1 (es)
SI (1) SI9300632A (es)
SK (1) SK93994A3 (es)
TW (1) TW276255B (es)
WO (1) WO1994013658A2 (es)
ZA (1) ZA939127B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
JP3304093B2 (ja) * 1994-09-13 2002-07-22 モンサント カンパニー 回腸の胆汁酸輸送及びタウロコール酸塩吸収の阻害活性を有する新規ベンゾチエピン類
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5952326A (en) * 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
ES2203239T3 (es) 1998-12-23 2004-04-01 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de agentes secuestrantes de acidos biliares para indicaciones cardiovasculares.
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU776664B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
NZ512536A (en) 1998-12-23 2003-11-28 G Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
IL143947A0 (en) * 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
JP2002533414A (ja) * 1998-12-23 2002-10-08 ジー.ディー.サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー.ディー. サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送(asbt)およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
KR102051030B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
WO2013152170A1 (en) 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593760A1 (de) * 1967-02-01 1972-06-08 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) * 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
US4066663A (en) * 1976-07-01 1978-01-03 Syntex (U.S.A.) Inc. 6,11-Dihydrodibenzo-[b. e.]-thiepin-11-one-3-aldehyde and 3-acetal derivatives
EP0076075B1 (en) 1981-09-25 1986-11-20 Beecham Group Plc Pharmaceutically active benzopyran compounds
US4416687A (en) * 1982-02-01 1983-11-22 Monsanto Company 3,5-Bis (trifluoromethyl)phenoxy carboxylic acids and derivatives thereof
NZ207110A (en) * 1983-02-15 1986-05-09 Merrell Dow Pharma (4a,11b)-3,4,4a,5,6,11b-hexahydro-2h-(1)benzoxepino(5,4,b)-1,4-oxazine derivatives and pharmaceutical compositions
AU597671B2 (en) * 1986-06-20 1990-06-07 Suntory Limited 2-Phenylbenzoxepin derivative
DE3726261A1 (de) 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
US4971982A (en) 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
GB8812765D0 (en) * 1988-05-28 1988-06-29 Beecham Group Plc Novel compounds
DE3831697A1 (de) * 1988-09-17 1990-03-22 Hoechst Ag 2,3,4,5-tetrahydro-1-benzoxepine, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3922392A1 (de) * 1989-07-07 1991-01-17 Merck Patent Gmbh Chromanderivate
JP3018386B2 (ja) * 1990-01-24 2000-03-13 吉富製薬株式会社 光学活性なベンゾチエピノピリダジン化合物の製造法

Also Published As

Publication number Publication date
FI943646A (fi) 1994-08-05
KR100236810B1 (ko) 2000-02-01
DE69324001D1 (de) 1999-04-22
HUT67852A (en) 1995-05-29
CA2129642A1 (en) 1994-06-23
IL107891A0 (en) 1994-04-12
JPH07503977A (ja) 1995-04-27
KR950700278A (ko) 1995-01-16
LT3167B (en) 1995-02-27
LV10451A (lv) 1995-02-20
CN1097752A (zh) 1995-01-25
RO113040B1 (ro) 1998-03-30
NZ258896A (en) 1996-03-26
EP0626954A1 (en) 1994-12-07
DK0626954T3 (da) 1999-10-11
ATE177742T1 (de) 1999-04-15
GR3030514T3 (en) 1999-10-29
US5602152A (en) 1997-02-11
EP0626954B1 (en) 1999-03-17
SI9300632A (en) 1994-09-30
LV10451B (en) 1995-12-20
DE69324001T2 (de) 1999-10-07
AU5697594A (en) 1994-07-04
HU9402302D0 (en) 1994-10-28
ZA939127B (en) 1994-08-05
WO1994013658A3 (en) 1994-08-04
SK93994A3 (en) 1995-04-12
RU2127268C1 (ru) 1999-03-10
PL174246B1 (pl) 1998-07-31
NO942914D0 (es) 1994-08-05
FR2698873A1 (fr) 1994-06-10
AU680856B2 (en) 1997-08-14
CN1050127C (zh) 2000-03-08
FI943646A0 (fi) 1994-08-05
CZ184894A3 (en) 1995-02-15
WO1994013658A2 (en) 1994-06-23
NO942914L (no) 1994-08-05
US5652252A (en) 1997-07-29
LTIP1525A (en) 1994-07-15
FR2698873B1 (fr) 1995-02-24
PL304719A1 (en) 1995-01-09
RU94040853A (ru) 1996-07-10
TW276255B (es) 1996-05-21

Similar Documents

Publication Publication Date Title
ES2132373T3 (es) Benzocicloheptenos, benzoxepinas y benzotiepinas.
MY109337A (en) Phenoxyl-and phenoxyalkyl-piperidines as antiviral agents
DE69925472D1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
GR3029471T3 (en) 2-substituted quinolines for treating leishmanioses.
ES2138623T3 (es) Derivados de pleuromutilina.
ATE225335T1 (de) Amide derivate als 5-ht1a liganden
TW372964B (en) Substituted 2-phenylpyridines, compositions containing same, processes for preparing same and their uses
GB2254613B (en) Anti-cancer anthracene compounds
ATE278676T1 (de) Imdazol-derivate, deren herstellung und deren verwendung als s-adenosylmethionin decarboxylase (=samdc) inhibitoren
NO994104D0 (no) 5-hydroksymetyl-2-aminotetraliner i form av kardiovaskulaere midler
TH16053A (es)
TW282458B (es)
DE69116680D1 (de) Imidazol-2-yl-derivate von bicyclischen verbindungen und verfahren zu deren herstellung
FR2695643B1 (fr) Dérivés d'uréido-acétamide, leur préparation et les médicaments les contenant.
DK0649426T3 (da) Inhibitorer af retrovirale proteaser

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626954

Country of ref document: ES